Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

NCT01184820 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

BIOLOGICAL: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)
BIOLOGICAL: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))

Sponsor

Bayer